Rapid Adoption of SPRINT PNS Systems: Milestones and Clinical Impacts

SPR Therapeutics announced that the SPR Therapeutics SPRINT PNS system has reached its 50,000th implant, reflecting rapid clinical uptake of a non‑opioid, 60‑day peripheral nerve stimulation therapy in ambulatory care.

Early adoption appears driven by the system’s minimally invasive, percutaneous 60‑day lead approach that avoids permanent implants while offering a defined treatment window for pain modulation. Clinically, the milestone suggests short‑term PNS is transitioning from niche use toward broader integration in multimodal, non‑opioid pain strategies and gaining acceptance among interventional pain practices as an alternative to longer‑term implants or opioid‑reliant pathways.

Reported clinical indications include chronic low back pain, post‑surgical and postoperative pain, joint‑related disorders (knee, shoulder), and neuropathic distributions, with use across outpatient and ambulatory procedural settings. The device’s percutaneous targeting of peripheral nerves can address both localized and radicular symptom patterns without general anesthesia or extended hospitalization. That practical scope matches observed trends toward diversified outpatient neuromodulation.

The company press release describes the RESET randomized trial comparing the 60‑day SPRINT PNS treatment versus usual care and reports that, per the company, the trial enrolled several hundred adults and used patient‑reported pain relief as the primary endpoint.

Adoption velocity appears to have accelerated: the device moved from about 30,000 to 50,000 implants in just over a year, suggesting faster uptake than earlier rollout phases and greater device familiarity among treating physicians. That pace implies expanding clinician training, more routine incorporation into outpatient pain workflows, and increasing payer engagement as case volume and published evidence grow—together positioning the 50,000th implant as a directional tipping point for mainstreaming short‑term PNS within non‑opioid pain management strategies.